OUR TEAM

Erasmus University Rotterdam, founded in 1913, is a leading Dutch university dedicated to creating positive societal impact through research and education. This mission is reflected within the Erasmus School of Health Policy & Management (ESHPM), where researchers bridge medicine, health, and social sciences. ESHPM stands out with strong expertise in health economics, health preference research, health technology assessment, and health policy, driving innovation and improvements in healthcare systems.

In UNIFIED, Erasmus University Rotterdam (EUR) is the Coordinator and Public Lead and helps shape its overall scientific direction. EUR brings a methodological perspective, with particular expertise in measuring what matters most to patients and translating these insights into clinical research and decision-making processes. EUR plays a key role in developing the UNIFIED Framework, ensuring that patient preference information, clinical outcome assessments, and digital health technology measures are meaningfully integrated. It also contributes across multiple work packages and disease-specific use cases, supporting collaboration between academia, clinicians, patient organisations, industry, HTA bodies, and regulators.

Through this work, Erasmus University Rotterdam helps ensure that UNIFIED delivers practical guidance that strengthens healthcare decisions and promotes truly patient-centred research across Europe and beyond.

The Institute for Outcomes Research at the Medical University of Vienna evaluates treatment effects while systematically incorporating the patient perspective. Its work focuses on establishing digitised endpoints, evidence-based care pathways, and clinical dashboards as key foundations for personalised medicine. The institute develops and implements digital health solutions, collects patient-reported data, and uses sensors and e-health applications to generate movement and activity profiles. By integrating these data sources, the team empowers patients, supports healthcare providers with innovative analytics, and contributes to improving the quality of care. The institute’s interdisciplinary team combines expertise in health and medicine with strong methodological and analytical capabilities.

In UNIFIED, the Institute for Outcomes Research leads Work Package 2, which focuses on the project’s use cases. In this role, the team provides strategic oversight, coordination, and methodological guidance across five medical domains. Work Package 2 is responsible for the empirical testing and validation of the framework and preliminary recommendations developed in Work Package 1, ensuring their applicability across complementary medical domains.

The institute’s contributions include conducting comprehensive landscape analyses, providing guidance on IRB protocols, hosting regular cross-site alignment meetings, and offering high-level methodological direction. Through these activities, the team helps ensure that the results generated in UNIFIED are robust, meaningful, and applicable across different disease areas.

Hochschule Neubrandenburg is a public higher-education institution in northern Germany with a distinct profile in research, development, and knowledge transfer. Within the Faculty of Health, Care and Management, the Professorship of Health Economics and Health Care Management conducts health services research on how innovative health interventions can be evaluated and integrated into care. Key activities include preference research, benefit and value assessment, and decision-support approaches that help make healthcare decisions more transparent and evidence-informed.

In UNIFIED, Hochschule Neubrandenburg serves as Co-Lead of Work Package 2 and provides methodological leadership for the obesity use case. The team’s contribution focuses on capturing and analysing patient preferences related to digitally collected indicators and health outcomes. This helps clarify what matters most to people and what drives acceptance and sustained use of digital solutions. Through this work, Hochschule Neubrandenburg contributes to UNIFIED’s overall objective of placing patient perspectives at the centre of evidence generation and decision-making across use cases and cross-cutting activities.

The University of Twente (UT) is a leading Dutch university that integrates technology and human‑centred approaches to address major societal challenges, including those in healthcare. Its health research is strongly supported by cross‑disciplinary collaboration through the Technical Medical Centre (TechMed) and the Health Technology & Services Research (HTSR) group, which specialises in patient preference research, health technology assessment, and health systems research.

Within UNIFIED, the HTSR group contributes its methodological expertise in patient preference research and digital health technology development. HTSR serves as the academic lead for Work Package 1, establishing the project’s methodological foundation. The team also acts as the methodological partner for the lung cancer use case and co‑leads Work Package 4, with a specific focus on ensuring meaningful patient engagement throughout the project.

Collaborate Project Management (CPM) is a Munich-based consultancy specialising in the management, coordination, and communication of international research and innovation projects. The organisation supports complex, multi-partner collaborations, particularly within European funding programmes, helping consortia manage projects effectively while ensuring that results are communicated clearly and reach the right audiences. CPM combines expertise in project coordination, stakeholder engagement, dissemination, and sustainability planning to maximise the impact of collaborative research initiatives.

In UNIFIED, Collaborate Project Management plays a key role in both project management and communication activities. CPM supports the coordination of the consortium, helping ensure smooth collaboration between partners, effective planning of project activities, and timely progress towards project goals. In addition, CPM co-leads the work on sustainability, dissemination, and communication, ensuring that UNIFIED’s results are shared widely and remain accessible beyond the lifetime of the project. This includes managing communication channels, supporting stakeholder engagement, and helping translate project outcomes into resources that can be used by researchers, clinicians, patients, industry, and decision-makers.

The University of Amsterdam is ambitious, creative, and committed. A leader in international science and a partner in innovation, the university has been inspiring generations since 1632.

The work in UNIFIED is carried out by the INtelligent Data Engineering Lab (INDElab), which is part of the Informatics Institute at the University of Amsterdam. The lab investigates AI systems that support people in their work with data and information from diverse sources. This includes addressing challenges related to the preparation, management, integration, and reuse of data.

In UNIFIED, the team focuses on the development and application of artificial intelligence. They are developing and advising on AI approaches that help connect different types of data and data sources to support analysis and reporting. This work contributes to better incorporating patient preferences into the evaluation of health interventions.

Founded in 1966, the University of Calgary is a top Canadian research-intensive university. Recognised as a leader in startup creation and research innovation, groundbreaking discoveries in child health are taking place at UCalgary. The UNIFIED University of Calgary team is based within the Cumming School of Medicine, an innovative medical school committed to excellence and leadership in education, research, and service to society. It is reimagining health for all, driving transformative change in medical education, clinical practice, biomedical, and health outcomes research.

Within UNIFIED, the University of Calgary is contributing expertise in health economics, including patient preferences research and health technology assessment, as well as patient-partnered research. They are leading the juvenile idiopathic arthritis use case building upon existing work in childhood arthritis UCAN CAN-DU/CURE (https://ucancandu.com) and continued collaboration in UNIFIED with The Hospital for Sick Children and Utrecht Medical Centre. The use case also leverages an ongoing meaningful partnership with Cassie+Friends including in the European Joint Programme on Rare Diseases (EJP-RD) funded PAVE project (https://cassieandfriends.ca/research-pave/), bringing deep experience in patient partnered research with an engaged patient community. In addition to the use case, University of Calgary is contributing to and leading or co-leading tasks related to the framework development component of UNIFIED and the development of consensus-based recommendations for implementation of the framework.

KU Leuven is one of Europe’s leading research universities, with a strong international reputation in biomedical sciences research. The university combines fundamental and applied research with a strong focus on societal impact. Within KU Leuven, the Department of Pharmaceutical and Pharmacological Sciences has extensive experience in patient preference and stakeholder engagement research, using both qualitative and quantitative methods. The department brings strong methodological expertise in stakeholder engagement, health outcomes research, and implementation science.

Within UNIFIED, KU Leuven plays a central coordinating role in stakeholder engagement and adoption activities. As the lead of Work Package 4, KU Leuven is responsible for developing and coordinating the project's overall stakeholder engagement plan. This includes mapping stakeholder needs, aligning engagement activities across work packages, and ensuring meaningful involvement of patients, clinicians, regulators, HTA bodies, and industry partners throughout the project lifecycle.

Through this work, KU Leuven helps ensure that the UNIFIED framework and recommendations are developed in close dialogue with end users, supporting their relevance, usability, and long-term adoption of project outputs across different stakeholder groups.

The Princess Máxima Center for Pediatric Oncology is the national centre in the Netherlands dedicated to comprehensive care and multidisciplinary research in childhood cancer. The centre also has a strong focus on survivorship, providing specialised care and conducting research on the long-term outcomes, late effects, and quality of life of childhood cancer survivors. Its mission is to cure every child with cancer while ensuring the best possible quality of life.

In UNIFIED, the Princess Máxima Center contributes to Work Package 2 and serves as the clinical lead for the use case on long-term childhood cancer survivors. Within this use case, the team applies its expertise in survivorship and late effects by conducting a patient preference study among survivors of childhood cancer. The study aims to better understand survivors’ preferences regarding patient-centred information and follow-up care, helping ensure that survivorship care reflects what matters most to patients.

UMC Utrecht (University Medical Center Utrecht) is one of the largest academic medical centres in the Netherlands. As part of Utrecht University, UMC Utrecht combines patient care, medical research, and education to advance healthcare and improve patient outcomes.

The institution is recognised for its strong focus on innovation, translational research, and collaboration across disciplines. Researchers and clinicians at UMC Utrecht work closely with patients, healthcare providers, and international partners to develop and evaluate new approaches to diagnosis, treatment, and healthcare delivery.

UMC Utrecht participates in international research collaborations that aim to improve how healthcare interventions are developed, assessed, and implemented in practice.

In UNIFIED, UMC Utrecht collaborates with partners across the consortium as part of the project’s effort to strengthen patient-centred approaches to healthcare research and decision-making.

The European Institute of Oncology (IEO) is a specialised cancer hospital in Milan founded in 1994 by Professor Umberto Veronesi. The institute combines comprehensive cancer care with clinical and translational research, with a strong focus on prevention, diagnosis, and treatment. Its patient-centred approach supports the integration of clinical data and research to advance innovative and personalised cancer care.

Within IEO, the Division of Thoracic Surgery, directed by Prof. Lorenzo Spaggiari, focuses on the surgical treatment of thoracic cancers, particularly primary and secondary lung tumours. The division is part of the institute’s Lung Program, an integrated clinical initiative that brings together multidisciplinary expertise to develop personalised treatment strategies for patients with lung cancer across all disease stages.

In UNIFIED, the European Institute of Oncology collaborates closely with the University of Milan to coordinate the lung cancer use case. This work focuses on improving patient care by enhancing telemedicine communication between patients, physicians, and caregivers, and by enabling teleconsultations among multidisciplinary teams. Remote, non-invasive digital health technology monitoring combined with web-based patient-reported outcome measures (PROMs) will support personalised follow-up care, improve tracking of disease progression, and help assess the impact of surgery and cancer therapies on patients’ quality of life. These insights will also contribute to evidence relevant for regulatory and HTA decision-making.

The Department of Health Sciences at the University of Milan (UMIL) is based at San Paolo Hospital in Milan and is part of the University’s School of Medicine. The department is a key centre for translational research, connecting basic, applied, and clinical sciences to improve healthcare. Its work focuses on developing personalised medicine approaches that take into account patients’ genetic, molecular, and clinical characteristics. The department also has strong expertise in patient preference research, helping ensure that treatments reflect patients’ values and lived experiences. In recent years, the team has also explored the use of artificial intelligence to support data-driven decision-making and the development of intelligent healthcare systems.

In UNIFIED, the University of Milan collaborates closely with the European Institute of Oncology to coordinate the lung cancer use case. This work focuses on improving patient care by enhancing telemedicine communication between patients, physicians, and caregivers, and by enabling teleconsultations among multidisciplinary teams. Remote, non-invasive digital health technology monitoring combined with web-based patient-reported outcome measures (PROMs) will support personalised follow-up care and help assess the impact of treatments on patients’ quality of life.

HUS Helsinki University Hospital is the biggest provider of specialised healthcare in Finland. Its high level of expertise is internationally recognised and accredited. As a university hospital, HUS is at the cutting edge of developing and evaluating treatment methods and clinical activities. HUS treats 700,000 patients every year. Its 26,500 professionals work to provide the best possible care for patients. HUS is responsible for organising specialised health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has also been centralised to HUS.

Within UNIFIED, HUS serves as the clinical lead for the Parkinson’s disease use case and also contributes to the obesity use case. HUS provides strong clinical expertise in both Parkinson’s disease and obesity, covering treatment, patient follow-up, and collaboration with patients. In addition, HUS contributes research and development expertise in digital health technologies related to both conditions. The clinical study of the Parkinson’s use case will be conducted by HUS in Finland. The clinical perspective and real-life experience on DHTs will be shared with industry and academic partners.

Jagiellonian University in Krakow, is the oldest university in Poland, established in 1364, and currently hosts over 37,000 students at 16 faculties. Guided by the motto “Inspired by the past, we shape the future,” the university combines centuries-old academic tradition with a modern approach to teaching. In 2025, over 1,000 medical research projects were carried out at Jagiellonian University Medical College, the medical faculty of the university, some of them in collaboration with universities and research institutions around the world.

The Jagiellonian University Medical College brings to UNIFIED its expertise in clinical studies on obesity. The same group of researchers has previously carried out several trials through collaboration in EU projects such as PREVENTOMICS, BIOCLAIMS and LIPGEN. As part of Work Package 2, the UJ team is responsible for carrying out the obesity use case (Task 2.6). Within the use case, the clinical study titled “Innovative use of digital health technology for improving the quality and effectiveness of obesity treatment” will involve recruitment of 300 adults living with obesity in Krakow. The study will identify and take into account the therapeutic goals preferred by patients living with obesity, which may be included as endpoints in future clinical trials on obesity.

Promptly is a digital health company dedicated to improving healthcare outcomes while reducing costs through the use of real-world evidence at scale. Working with healthcare providers, life sciences companies, and health insurers across Europe and Latin America, Promptly builds secure Health Data Infrastructures that enable organisations to unlock the value of their data and collaborate in meaningful real-world research and innovation without moving their data. Its federated solutions support outcome-based care, clinical research, and data-driven decision-making, while ensuring strong data protection, privacy, regulatory compliance, and scalable, interoperable digital health ecosystems worldwide.

Within the UNIFIED project, Promptly contributes its expertise in digital health and health data infrastructures. The company supports the definition of data architectures and requirements that enable the combined use and analysis of patient-reported information, clinical assessments, and data generated through digital health technologies. Promptly also contributes to the application of these architectures across project use cases, helping translate methodological guidance into practical, real-world implementations. This role supports UNIFIED’s objective of enabling scalable, patient-centred, and interoperable digital endpoints.

The Progress and Health Foundation (FPS) is a public organisation that provides central support and management for research within the Andalusian Public Health System in Spain. Its mission is to promote health innovation and excellence in order to meet the health needs of citizens. Within FPS, the Andalusian Health Technology Assessment Agency (AETSA) specialises in supporting evidence-based healthcare decision-making. AETSA works to improve health outcomes, quality, and equity while ensuring the sustainability of the health system through active participation in national and international assessment networks.

AETSA contributes to UNIFIED by helping bridge the gap between patient-needs data and formal evaluation processes, supporting the project’s objective of making healthcare decisions more reflective of patient value. The team contributes to establishing the methodological foundations in Work Package 1 and leads the HTA adoption strategy in Work Package 4. In addition, AETSA will identify implementation and dissemination pathways and coordinate with European health systems to support the practical uptake of project results. By integrating the Patient Involvement Process with HTA requirements, AETSA helps ensure that digital health technology–derived endpoints and patient perspectives can be effectively implemented by healthcare authorities and stakeholders across Europe.

The European Patients’ Forum (EPF) is an independent, non-profit, non-governmental umbrella organisation representing over 80 patient organisations across Europe, including EU-level disease-specific associations and national patient coalitions. EPF’s mission is to advance the interests of patients and their communities by strengthening their collective impact across Europe through effective advocacy, education, empowerment, and partnership. The organisation works to strengthen patient involvement in health policy, research, and innovation, and to build the capacity of patient communities to engage meaningfully in decision-making processes. Its core expertise lies in patient engagement, advocacy, and promoting transparency and trust in healthcare systems.

In UNIFIED, EPF plays a key role in ensuring that patient perspectives guide every stage of the work. EPF helps ensure that the evidence-based framework developed by UNIFIED is practical, sustainable, and accessible, and that it reflects patients’ daily realities, needs, and priorities. Through stakeholder engagement, co-creation, and communication activities, EPF supports the project’s objective of delivering inclusive, trustworthy solutions aligned with what truly matters to patients.

Cassie + Friends is a Canadian national charity supporting children and youth with juvenile arthritis and other childhood rheumatic diseases. For more than 18 years, the organisation has worked alongside families, paediatric rheumatology teams, and researchers to ensure that children are supported early and meaningfully included in decisions that shape their care. Its core expertise lies in embedding trusted family support within care pathways. Cassie + Friends delivers Family Navigation from diagnosis onward, helps reduce treatment barriers through practical supports, hosts family connection and education events, and leads patient partnership in national and international research. Through its “Care to Cure” approach, the organisation turns lived experience into evidence and translates family insight into measurable improvements in care and policy.

In UNIFIED, Cassie + Friends contributes to Work Package 2 through the Juvenile Idiopathic Arthritis (JIA) use case, bringing forward patient and parent perspectives on meaningful clinical endpoints, including pain, daily functioning, fatigue, mental health, and quality of life. The organisation also helps assess the use of digital health technologies in trials, ensuring that data collection is practical, acceptable, and manageable for families navigating complex care. As JIA representatives within the Patient Advisory Group, Cassie + Friends contributes to shaping patient-centred engagement standards across the broader project.

The SickKids Research Institute, part of The Hospital for Sick Children (SickKids) in Toronto, is Canada’s largest hospital-based child health research institute. It conducts and translates groundbreaking research, trains the next generation of researchers, and supports global scientific communities with knowledge and state-of-the-art facilities. Through its work, the institute aims to accelerate the translation of discoveries from the laboratory to clinical care, helping improve the lives of children around the world, sooner.

In UNIFIED, the research team at SickKids Research Institute contributes to the identification of patients for the project. Clinical research professionals and programmers will identify potential participants and enrolment sites across Canada through an established multicentre study, and will support the lead site in developing the recruitment workflow for the UNIFIED project. This work will help ensure efficient and coordinated recruitment of participants for the study.

Childhood Cancer International – Europe (CCI Europe) is the leading European umbrella organisation for childhood cancer parent, patient, and survivor groups, as well as other childhood cancer organisations across Europe. It unites 66 member organisations in 37 countries.

CCI Europe envisions a world where everyone affected by childhood cancer is supported and able to thrive without lasting impact. The organisation unites and represents the European childhood cancer patient community to drive change that improves lives. It empowers its members to amplify their individual and collective impact, mobilises the community, and coordinates joint actions to tackle shared challenges.

In UNIFIED, CCI Europe ensures that the perspectives of patients and families are included in developing and testing a patient-centred framework. In Work Package 2, CCI Europe helps design and test the paediatric radiation oncology use case, collects patient preference data, supports the use of outcome measures and digital health tools, and shares key lessons from this field. In Work Package 4, CCI Europe leads stakeholder consultations, supports the Patient Advisory Group, builds patient capacity, and contributes to developing a practical strategy to ensure the framework is widely accepted and used across Europe and beyond.

The Pan-European Health Outcomes Observatory (PEO) of H2O is a not-for-profit, multi-stakeholder initiative dedicated to standardising and integrating patient health outcomes data across Europe. Its mission is to build a patient-centric data governance framework based on harmonised outcome domains and robust data trust principles. By creating interoperable, standardised frameworks for capturing and linking patient-reported outcomes with clinical data, PEO enables the generation of high-quality real-world evidence that reflects what truly matters to patients.

Within UNIFIED, PEO contributes expertise on standardised outcome frameworks that can be leveraged to refine UNIFIED’s evidence integration methods across use cases and work packages, particularly those focused on harmonisation and consensus methodologies. By promoting harmonised outcome frameworks and interoperable data approaches, PEO strengthens the project’s efforts to align patient preferences, clinical outcome assessments, and digital health measures. This contribution supports UNIFIED’s objective of defining meaningful, patient-centred evidence capable of informing regulatory, HTA, and clinical decision-making across Europe.

PanCare is a pan-European network of healthcare professionals, researchers, survivors of childhood, adolescent, and young adult (CAYA) cancer, and their families. Its mission is to ensure equal access to optimal long-term follow-up care and to improve the quality of life for every CAYA cancer survivor.

PanCare works towards this mission through research, guideline development, awareness raising, and survivor empowerment. The network conducts and supports research on late effects and the improvement of long-term follow-up care, and develops evidence-based guidelines for survivorship care. PanCare also advocates for the importance of long-term follow-up to improve the health and wellbeing of CAYA cancer survivors, and supports survivors in taking an active role in their care and decision-making by developing plain-language information and resources.

In UNIFIED, PanCare focuses mainly on the paediatric radiation oncology survivorship use case. The organisation contributes its expertise in guideline development and applies its experience in developing survivorship care plans from previous projects. PanCare also engages its network to gather input from healthcare professionals, survivors, and other stakeholders involved in survivorship care, helping ensure that the project reflects the needs and experiences of the childhood cancer survivor community.

The European Academy of Neurology (EAN) is a non-profit, independent professional organisation representing over 45,000 neurologists and 48 national neurological societies across Europe. Its mission is to promote neurological excellence and reduce the burden of neurological diseases, improving patient care and outcomes through collaboration, research, education, and advocacy. EAN serves as a major healthcare-professional body, offering continuous medical education through initiatives such as eanCampus, educational schools, and congress, as well as career development, scientific publications, and evidence-based clinical practice guidelines that help harmonise diagnosis and treatment standards across Europe.

In UNIFIED, EAN serves in an advisory capacity within Work Package 2 and has nominated six experts in movement disorders, with specific expertise in Parkinson’s disease (PD), to contribute their knowledge on clinical practice guidelines for PD. Within Tasks 2.2 and 2.8, EAN provides expert advice on the design of the Parkinson’s disease use case and helps identify gaps between the planned use cases and the project's preliminary recommendations. The organisation also contributes to analysing gaps in existing clinical practice guidelines, particularly regarding patient preferences, clinical outcome assessments, and digital health technologies. Based on the project's findings, EAN will also contribute to drafting proposals for updating the clinical practice guidelines for Parkinson’s disease.

The European Coalition for People Living with Obesity (ECPO) is a patient-led organisation representing people living with obesity across Europe. ECPO works to reduce stigma and discrimination, promote recognition of obesity as a complex chronic disease, and ensure that the voices of people living with obesity are reflected in research, policy, and healthcare decision-making.

Through advocacy, collaboration, and engagement with policymakers, clinicians, and researchers, ECPO promotes greater patient involvement in healthcare and research. The organisation works closely with European and international stakeholders to improve understanding of obesity and support better prevention, treatment, and care.

ECPO is part of the UNIFIED consortium, contributing the perspective of people living with obesity and supporting collaboration between patient organisations, researchers, healthcare stakeholders, and industry partners.

Parkinson’s Europe, founded in 1992, is the only European umbrella patient organisation dedicated to Parkinson’s. Its members are national Parkinson’s organisations across Europe. By bringing together its member organisations, people diagnosed with Parkinson’s, their families, supporters, and other key stakeholder groups, Parkinson’s Europe creates a united European Parkinson’s voice that it amplifies at both European and global levels. The organisation’s vision is that people with Parkinson’s and their families have access to the highest standards of treatment, support, and care needed to live full and comfortable lives. Its mission is to work and campaign with people with Parkinson’s, their partners, families, and supporters across Europe to ensure their voices are heard and represented. As the leading voice for Parkinson’s in Europe, Parkinson’s Europe provides trusted information, advances and shares good practices, raises awareness and improves understanding of the condition, and facilitates research collaboration.

In UNIFIED, Parkinson’s Europe serves as the Patient Organisation Lead for the Parkinson’s disease use case. The organisation collaborates with other patient organisations in the consortium to share insights, connect patient perspectives across disease areas, and contribute to the development of the Patient Advisory Group. Parkinson’s Europe also supports the integration of patient perspectives across the project’s work packages, helping ensure that the project’s outcomes remain relevant and meaningful for people living with Parkinson’s and their families.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, based in Rome, Italy, is a major university hospital affiliated with the Catholic University of the Sacred Heart. The institution combines clinical care, medical education, and scientific research across a wide range of medical disciplines.

As a leading academic medical centre, the hospital is involved in national and international research collaborations focused on improving patient care and advancing medical knowledge. Its clinicians and researchers contribute to studies that aim to translate scientific discoveries into improved diagnosis, treatment, and healthcare delivery.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS participates in the UNIFIED consortium as a clinical and academic partner, collaborating with other organisations across Europe and beyond.

Pfizer applies science and global resources to bring therapies to people that extend and significantly improve their lives. The company strives to set the standard for quality, safety, and value in the discovery, development, and manufacture of healthcare products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. As one of the world’s leading innovative biopharmaceutical companies, Pfizer collaborates with healthcare providers, governments, and local communities to support and expand access to reliable and affordable healthcare worldwide. For more than 175 years, Pfizer has worked to make a difference for all who rely on its medicines and vaccines.

Within UNIFIED, Pfizer serves as the industry lead partner, supporting the project’s ambition to embed patient priorities in healthcare decision-making. Pfizer co-leads Work Packages 3, 4, and 6, as well as the lung cancer use case, contributing clinical, methodological, and regulatory expertise. Through this role, Pfizer helps develop a harmonised framework that integrates patient preference information, clinical outcome assessments, and digital health technology data to deliver practical, patient-centred outputs.

AbbVie Inc. is a global biopharmaceutical company focused on discovering and developing innovative medicines for serious and complex diseases. The company works across several therapeutic areas, including immunology, oncology, neuroscience, and eye care.

AbbVie combines scientific research, clinical development, and collaboration with partners across the healthcare ecosystem to advance new treatments and improve patient outcomes. Through partnerships with academic institutions, healthcare providers, and patient organisations, the company contributes to research addressing unmet medical needs.

AbbVie participates in the UNIFIED consortium as one of the industry partners collaborating with academic, clinical, and patient organisations in the project.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialisation of innovative medicines. The company’s research spans several therapeutic areas, including oncology, cardiovascular and metabolic diseases, respiratory conditions, and rare diseases.

AstraZeneca works closely with academic institutions, healthcare providers, and patient organisations to advance scientific knowledge and develop treatments that address significant medical needs. Through its research and development activities, the company contributes to innovation in healthcare worldwide.

AstraZeneca participates in the UNIFIED consortium alongside partners from academia, healthcare, patient organisations, and industry.

GenAIz has created a novel, ethical, and data compliant AI solution designed to increase workflow efficiency across pharmaceutical and life sciences applications. The company's core expertise lies at the intersection of data orchestration, regulatory compliance, and artificial intelligence. Within the UNIFIED project, this expertise is applied by sharing our experience and expertise and how it can affect patient-centred clinical-study endpoints derived from digital health technologies.

In UNIFIED, GenAIz contributes to the development of technical architecture and requirements, supports the creation of evaluation benchmarks for the project's methodological framework. The company also provides evidence-based guidance for specific use cases and explores AI algorithms for pooled measures across datasets. In addition, GenAIz, conducts state-of-the-art analyses across several project use cases, including Parkinson's disease, obesity, juvenile idiopathic arthritis, lung cancer, and paediatric radiation oncology. GenAIz also contributes to the UNIFIED AI Review Board, supporting responsible and effective use of AI within the project.

F. Hoffmann-La Roche AG (Roche) is a global healthcare company headquartered in Switzerland. Roche focuses on pharmaceuticals and diagnostics, with a strong emphasis on developing innovative medicines and personalised healthcare solutions.

The company collaborates with researchers, healthcare professionals, and patient communities around the world to advance medical science and improve treatment outcomes. Roche’s research and development activities cover several major disease areas, including oncology, neurology, immunology, and rare diseases.

Roche is part of the UNIFIED consortium, contributing to the collaborative work carried out by partners from academia, healthcare, patient organisations, and industry.

Janssen, the pharmaceutical companies of Johnson & Johnson, focuses on developing medicines and healthcare solutions to address serious diseases across several therapeutic areas, including oncology, immunology, neuroscience, and infectious diseases.

Through scientific research and collaboration with partners across the healthcare ecosystem, Janssen works to advance medical innovation and improve patient outcomes. The organisation collaborates with academic institutions, healthcare providers, and patient organisations worldwide.

Janssen participates in the UNIFIED consortium as one of the industry partners collaborating with other organisations in the project.

John Snow Labs, the AI for Healthcare company, provides state-of-the-art software, language models, and data to help healthcare and life science organisations build, deploy, and operate AI, large language model, and natural language processing projects faster. Its mission is to make healthcare data more usable, reliable, and impactful for research, clinical decision-making, and public health.

Within UNIFIED, John Snow Labs contributes expertise in artificial intelligence and digital health technologies. The organisation supports the integration of patient preference information, clinical outcome assessments, and digital health technology–derived measures by applying healthcare-trained language models and curated biomedical data resources. Its role includes helping to extract, structure, and standardise patient-centred information across studies and care settings, ensuring that these data can be meaningfully combined and evaluated. John Snow Labs also contributes to defining evaluation standards and technical approaches that ensure AI methods are accurate, responsible, and aligned with the project’s governance framework. Through these contributions, the company supports UNIFIED’s objective of developing a harmonised, evidence-based framework that better reflects what matters most to patients in healthcare decision-making.

Mölnlycke Health Care is a global MedTech company that develops medical products and solutions designed to improve patient outcomes and support healthcare professionals. The company focuses on areas such as wound care, surgical solutions, and infection prevention.

Mölnlycke works with healthcare providers and researchers worldwide to develop products that support safer and more efficient healthcare delivery. Its activities combine research, product development, and collaboration with healthcare stakeholders.

Mölnlycke Health Care participates in the UNIFIED consortium alongside partners from academia, healthcare organisations, patient groups, and industry.

Novartis is a global pharmaceutical company headquartered in Switzerland, focused on developing innovative medicines to address serious diseases. Novartis works across a wide range of therapeutic areas and is committed to improving patient outcomes through scientific innovation, data-driven research, and collaboration across the healthcare ecosystem.

In UNIFIED, Novartis contributes an industry perspective to the development of the UNIFIED Framework. As a pharmaceutical partner, Novartis brings expertise in clinical research, drug development, and the evaluation of treatment outcomes. Its involvement helps ensure that patient preference information, clinical outcome assessments, and digital health technology measures can be meaningfully integrated into clinical studies and healthcare decision-making. By collaborating with academia, clinicians, patient organisations, industry partners, HTA bodies, and regulators, Novartis supports UNIFIED’s ambition to strengthen how patient-centred evidence is generated and applied in practice.

Through this contribution, Novartis helps advance more patient-focused approaches to innovation and healthcare decision-making.

Novo Nordisk is driven to defeat serious chronic diseases, focusing on changing diabetes, obesity, and other rare blood and endocrine disorders. The company strives to improve lives by pioneering scientific breakthroughs and expanding access to care. Its main activities include the research and development of innovative biological medicines, the manufacturing protein-based pharmaceuticals using biotechnology, and the global distribution of diabetes and obesity medications, including Ozempic®, Wegovy®, and various insulin products. Novo Nordisk also provides patient education and support programs, advocates for improved healthcare access, and pursues sustainability initiatives and environmental responsibility. With nearly 100 years of experience, Novo Nordisk employs approximately 63,000 people globally and markets products in over 170 countries.

Within UNIFIED, Novo Nordisk brings an industry perspective on patient-centred digital endpoints and outcomes methodology. The company co-leads Work Package 1, shaping the project’s methodological foundation for integrating patient preference information, clinical outcome assessments, and digital health technology measures, and for defining patient-centred AI approaches to combine these data types. Novo Nordisk’s core expertise in this area helps ensure that the framework and taxonomy are both scientifically rigorous and operational for industry adoption. This contribution supports UNIFIED’s objectives of developing an evidence-based framework, consensus recommendations, and transferable methods that regulators, HTA bodies, clinicians, and industry can implement across disease areas.

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably.

Its portfolio of products, services, and solutions is at the centre of clinical decision-making and treatment pathways. Patient-centred innovation has been and always will be at the core of the company’s work, with the aim of creating better outcomes and experiences for patients regardless of where they live or the challenges they face. As Siemens Healthineers expands its focus on cancer care, the company is leveraging the deep learnings from its Varian products and services to bring more personalised care for patients.

Within UNIFIED, Siemens Healthineers contributes to building an evidence-based framework to integrate patient preference information, clinical outcome assessments, and digital health technology–derived measures into healthcare decision-making. The company also contributes to defining clinical study endpoints that reflect what is meaningful to patients.

As part of the project, Siemens Healthineers conducts a clinical study with Policlinico Gemelli University Hospital to evaluate the preferences of paediatric cancer patients and their caregivers regarding the delivery of educational interventions developed through the company’s empowerME programme. This education and engagement initiative includes tools designed to reduce patient distress and support clinical sites that may lack resources to educate patients and families during challenging periods. The study will also monitor patients’ mood using digital health technologies alongside traditional assessment instruments.

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions that aim to transform the lives of people living with severe diseases of the immune system and the central nervous system. The company employs more than 9,000 people in approximately 40 countries. UCB believes that the future of healthcare is one where every decision is shaped by what truly matters to patients.

Within UNIFIED, UCB contributes its expertise alongside leading universities, hospitals, patient organisations, and industry partners. Over the course of the project, the company supports the development of an evidence-based framework that provides clear guidance for integrating patient-centred data into healthcare decision-making. This includes contributing to approaches that incorporate patient perspectives across the full healthcare lifecycle, from research and development to regulatory review and clinical practice.

IQVIA is a leading global provider of clinical research services, commercial insights, and healthcare intelligence for the life sciences and healthcare industries. IQVIA’s Patient Centered Solutions (PCS) team is a global leader in the science of measuring meaningful patient outcomes. PCS provides comprehensive, global solutions for patient experience data (PED), combining endpoint and PED strategy, patient preference research, outcomes research, instrument licensing and development, and expert Clinical Outcome Assessment (COA) design and implementation. For more information visit https://bit.ly/IQVIA-PCS.

IQVIA contributes to UNIFIED by providing methodological expertise in patient preference research, COAs, digital health technologies, as well as industry and regulatory/HTA expertise, supporting the design, execution, and interpretation of project activities. Through its involvement, IQVIA provides in-kind contributions to Work Packages 1, 2, 3, and 5. This contribution supports UNIFIED’s vision of a harmonised, internationally aligned approach integrating patient-centred clinical-study endpoints.

Amgen is a global biotechnology company dedicated to discovering, developing, and delivering innovative medicines for serious illnesses. The company focuses on areas such as oncology, cardiovascular disease, inflammation, bone health, and rare diseases.

Amgen combines advanced science and biotechnology with clinical research to develop therapies that address significant medical needs. Through collaborations with researchers, clinicians, and patient organisations, the company contributes to advancing biomedical innovation.

Amgen participates in the UNIFIED consortium alongside partners from academia, healthcare organisations, patient groups, and industry.

Pfizer R&D UK Limited participates in UNIFIED as an associated partner "case b" of Pfizer Inc. Its contributions are integrated within the activities led by the main partner.

Pfizer Limited participates in UNIFIED as an associated partner "case b" of Pfizer Inc. Its contributions are integrated within the activities led by the main partner.

Pfizer International Operations participates in UNIFIED as an associated partner "case b" of Pfizer Inc. Its contributions are integrated within the activities led by the main partner.

Pfizer Pharma GmbH participates in UNIFIED as an associated partner "case b" of Pfizer Inc. Its contributions are integrated within the activities led by the main partner.

AstraZeneca Pharmaceutical LP participates in UNIFIED as an associated partner "case b" of AstraZeneca AB. Its contributions are integrated within the activities led by the main partner.

Evinova AB participates in UNIFIED as an associated partner "case b" of AstraZeneca AB. Its contributions are integrated within the activities led by the main partner.

Janssen Cilag Limited participates in UNIFIED as an associated partner "case b" of Janssen Biologics BV. Its contributions are integrated within the activities led by the main partner.

Janssen Research & Development, LLC participates in UNIFIED as an associated partner "case b" of Janssen Biologics BV. Its contributions are integrated within the activities led by the main partner.

IQVIA LTD participates in UNIFIED as an associated partner "case b" of IQVIA Solutions Belgium. Its contributions are integrated within the activities led by the main partner.

Amgen Inc participates in UNIFIED as an associated partner "case b" of Amgen. Its contributions are integrated within the activities led by the main partner.

Varian Medical Systems Inc participates in UNIFIED as an associated partner "case b" of Siemens Healthineers AG. Its contributions are integrated within the activities led by the main partner.